Yeo Laboratory
Developing new treatments for patients with solid cancer tumours.
Through extensive clinical collaborations, the Yeo Laboratory develops patient-derived models (3D organoids) and liquid biopsy biomarkers (circulating tumour cells), to enable non-invasive real time monitoring and evaluation of innovative cancer therapies such as targeted and cellular immunotherapies.
The Yeo Lab aims to understand why cancers behave differently from person to person, and what drives these differences at a biological level. By uncovering the unique factors that shape each individual’s cancer, the team hopes to help develop more personalised and precise treatments that are truly relevant to patients in the clinic.
- Solid tumours
- Liquid biopsy
- Organoids
- CAR-T cells
- Organoids
- Mice models
- Cancer therapy
-
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
-
Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
-
High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer
- Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging
People
-
Dr Dannel Yeo
Laboratory Head
-
Heidi Strauss
Research Assistant -
Anna Leach
Research Assistant -
Dr Samuel Smith
PhD student -
Dr Christine Lee
Research Officer -
Dr Helen Ke
PhD student -
Dr Sharon Sagnella
Visiting Researcher -
Luigia Manzoni
Visiting Researcher -
Dr Madeleine Strach
Visiting Researcher -
Lucy Yasenev
Visiting Researcher -
Dr Bilal Malik
Visiting Researcher -
Stephen O’Brien
Visiting Researcher -
Dipshika Lal
Visiting Researcher
Student opportunities
To learn more about student opportunities in the Yeo Laboratory and for all general enquiries relating to our work, please contact Dr Dannel Yeo.
Current opportunities:
Identifying Circulating Tumour Cells through patient liquid biopsies
Project details
Primary Supervisor: Dr Dannel Yeo
Supervisory Team: Anna Leach, Christine Lee
Centre: Cancer Innovations
Projects: Honours, Masters or PhD
Our laboratory aims to improve low surviving cancers (pancreatic cancer, small cell lung cancer, mesothelioma, peritoneal, appendiceal, and colorectal cancer) through a personalised approach using liquid biopsy (circulating tumour cells) and patient-derived organoids (3D culture models). We utilize next generation liquid biopsy technology to detect and isolate rare cancer cells in the blood as a diagnostic and prognostic biomarker. Through single-cell characterisation, we can obtain molecular insights in a non-invasive manner. We also explore novel therapies such as targeted therapy and CAR-T cellular immunotherapy to target cancer vulnerabilities and obtain cures. We work closely with our clinical collaborators at Royal Prince Alfred Hospital and Chris O’Brien Lifehouse to ensure our findings have the best possible outcomes for cancer patients. Our translational research projects can be tailored to suit Honours, Masters or PhD degrees.